# Ligand (LGND) — News

LGND · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/lgnd/news

## Recent headlines

- [Orchestra Biomed - Primary endpoint data to be submitted for presentation at cardiovascular conference in Q2 2027](https://www.ainvest.com/news/orchestra-biomed-primary-endpoint-data-submitted-presentation-cardiovascular-conference-q2-2027-2610) — AInvest Wire, Oct 1, 2026
  Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has outlined a timeline for the submission of primary endpoint data from its BACKBEAT Trial, which is evaluating AVIM Therapy for the treatment of uncontrolled hypertension in pacemaker-indicated patients. The company, in collaboration with Medtronic,…
- [Arecor Therapeutics - Close of accelerated bookbuild to new orders](https://www.ainvest.com/news/arecor-therapeutics-close-accelerated-bookbuild-orders-2609) — AInvest Wire, Sep 30, 2026
  Arecor Therapeutics PLC (AIM: AREC) has announced the close of an accelerated bookbuild to new orders, raising capital through the monetisation of royalty and technology access fee streams from its portfolio assets. The company has entered into a royalty financing agreement with Ligand…
- [Arecor Therapeutics - Launches fundraising to raise up to GBP 5.13 mln](https://www.ainvest.com/news/arecor-therapeutics-launches-fundraising-raise-gbp-5-13-mln-2609) — AInvest Wire, Sep 30, 2026
  Arecor Therapeutics PLC (AIM:AREC) has announced plans to launch a fundraising initiative aimed at raising up to GBP 5.13 million to support its ongoing development programs and operational requirements. The company, which focuses on diabetes and cardiometabolic treatments, has previously secured…
- [Ligand Pharmaceuticals Incorporated - Commits up to $6 mln in Series C financing](https://www.ainvest.com/news/ligand-pharmaceuticals-incorporated-commits-6-mln-series-financing-2609) — AInvest Wire, Sep 24, 2026
- [Ligand Pharmaceuticals Incorporated: Citigroup raises target price to $397 from $390](https://www.ainvest.com/news/ligand-pharmaceuticals-incorporated-citigroup-raises-target-price-397-390-2609) — AInvest Wire, Sep 23, 2026
  Citigroup analyst Yigal Nochomovitz has raised the price target for Ligand Pharmaceuticals (LGND) to $276 from $270, maintaining a 'Buy' rating for the biopharmaceutical company. This adjustment reflects a 2.22% increase in the firm’s target price. The move follows a series of positive analyst…

## Similar Stocks

- [ANIP](https://www.lighthorse.io/tickers/anip) — ANI Pharmaceuticals, Inc. - Common Stock
- [ADMA](https://www.lighthorse.io/tickers/adma) — ADMA Biologics Inc - Common Stock

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).